Our services

ADC Review
is made possible by:

Media Kit 2017 – 2018

About the Journal
Editorial Focus
Our Readers
Editorial Submission Guidelines
Website Underwriter/Sponsorship

About the Journal

ADC Review / Journal of Antibody-drug Conjugates (ISSN: 2327-0152) is an international, hybrid open-access, peer-reviewed journal designed to serve the needs of a diverse community of individuals from academia, life sciences, (bio) pharma, as well as basic, translational and clinical research and clinicians along with regulatory affairs, government authorities, representatives from payers, and policymakers.

This comprehensive journal with key information includes peer-reviewed articles, news, discussions, editorials/Op-Eds, blogs, and an educational center with the latest and most relevant information about antibody drug conjugates, (ADCs), biSpecific antibodies, site-specific antibody drug conjugates, small-molecule drug conjugates, (SMDC), and engineered antibody fragments, etc.

Advisory and review boards
Our advisory and review boards are made up of key individuals from across the global medical, life science, pharmaceutical industries as well as important academic, clinical/treatment centers, and regulatory/government agencies


  • To help all stakeholders gain insight into engineering and optimizing novel, next-generation antibody-drug conjugates
  • Transforms the way industry and science exchanges information
  • A single source of information covering everything related to ADCs
  • An industry job board offering the very best in online recruitment functionality and industry practices
  • ADC Review /Journal of Antibody-drug Conjugates offers an “all you need to know” ongoing and updated educational and training center
  • An overview of major medical society meetings and educational conferences
  • Our advisory and review boards are made up of key individuals from across the global medical, life science, pharmaceutical industries as well as important academic, clinical/treatment centers, regulatory/ government agencies

Editorial Focus

News and development Clinical trail updates Clinical applications Drug development
Analysis and characterization Manufacturing Regulatory challenges Data integrity
Conjugation technology ADC construct Pharmacokinetic/dynamic relationships Case studies
Product based information (drug descriptions) Emerging technologies Mass Spectrometry  Linker Chemistry

Our Readers

Large Drug Development (Pharma / Biotech) Small and Medium Drug Development Equipment Manufacturers
Contract Clinical Research Organizations Physicians and Clinicians Contract Development and Manufacturing / Services Organizations
Regulatory and Government Agencies Platform Technology Development Academia

Traffic Growth:  

16,983 (unique) monthly readers (August 29, 2017)

Editorial Submission Guidelines

Company Profile
Can be included in our Annual Resource Guide. Please provide your company logo (PNG or GIF), link to your website and up to a 200 word description of your company.

News Articles
Should be between 750 and 2,100 words and cover a range of news related subjects (information will be edited by our team). While these articles cover news, they are not the same as a press release. In these articles we strive to cover news without bias. Note that we do require references (3 – 5) to peer reviewed journals. Illustrations, graphs/tables and photos can be included.

Provide a commentary/opinion and can include a number of topics including: early discovery, (pre)clinical development, clinical trials, characterization and analytics, manufacturing, regulatory/ government/legal, industry issues, etc.). They are between 750 and 2,500 words in length and includes 3 – 5 references to peer reviewed journals. Editorials can also include 3 – 5 illustrations/ graphs and/or photos. Finally, for each editorial we like to include an author profile (500 words + profile picture). While a clear reference can be made to the company, editorials should primarily be a commentary or opinion based on the selected topic and showcase the expertise/opinion of the authors. Editorials can be submitted for peer review, but this is not required.

Manuscripts for Peer Review
To be published in our reviewed article section, includes original studies, reviews, case studies or ‘legal/regulatory’ update. They can be between 750 and 3,500 words in length and include at least 5 references to peer reviewed journals. Depending on the topic, there is no real limit to the number of illustrations/images/graphs. Finally, for each submitted article we like to include author profiles (500 words + profile picture) of all authors (multiple authors possible). Note that each accepted/ published peer reviewed article will be indexed and receive a DOI registration (for our journal this is: DOI: 10.14229/ jadc{unique article qualifier}).

Q & A/Interviews
Are based on a select number of questions we’ll submit to you and can be answered by email. Interviews can include a range of topics, as well as discuss company specific expertise.

ADC Review University
Includes articles that are primarily educational in nature. Hence, references to peer reviewed journals are required. The length of these articles, as well as supporting materials (illustrations, etc.) depends on the topic. This section can also include video programs or podcasts and eBooks/white papers (see below).

Time to publishing
Can take up to 4 weeks following submission of a manuscript for peer review to be published (if accepted by our review board). For other articles the lead time may be shorter.

Website Underwriter/Sponsorship

Position your brand across ADC Review / Journal of Antibody-drug Conjugates. Includes banner advertising run of site and designation of “Made possible by…” Custom Resource Library

Turnkey solution to get your content in front of your target audience and capture leads.

Editorial Series Underwriter
Drive the conversations that matter most to your brand. Directly support and influence the development of educational editorial coverage.

ADC University Underwriter
ADC University is aimed at providing our readers a comprehensive resource for the rapidly evolving landscape ADC innovations. We are looking to partner with underwriters to help develop online training courses and other interactive resources.

Creative Services
Let us help you craft your message to influence your target audience. We offer a complete suite of services that include writing, design, videography, social media and strategy.

eBooks / White Paper / Product Monograph
As a part of our promotional publishing activities, we’ll start developing downloadable eBooks and White Papers with our underwriters. For pharmaceutical companies we will also start developing Product Monographs. For each of the published and downloadable publications we will create unique lead pages linked to the journal. Commercial leads will be shared with the sponsoring underwriter.

In today’s world, a traditional webinar may not enough to reach your audience. It is important to develop and deliver great webinars that really stand out. The team behind ADC Review / Journal of Antibody-drug Conjugates offers a complete suite of services to help you deliver your message in an unique professional broadcast environment.  Our team helps you to demonstrate your thought leadership, offers premium branding and targeting exposure and promotion through our specialized social media channels.

Summary: Why Sponsor or Advertise?

We Help You Target Your Prospects:
Advertise in ADC Review / Journal of Antibody-drug Conjugates to build your brand identity among hard-to-reach professionals throughout the year;

We help You to Focus on Your Market:
ADC Review / Journal of Antibody-drug Conjugates attracts readers which are recognized as subject-matter experts/Key Opinion Leaders (KOL) and have unparalleled influence within their own company and in the industry;

Find Key Decision Makers:
Our sponsorship and advertising options let you build market awareness among the pharmaceutical and medical professionals most likely to influence buying decisions.

adc_reviev_enewsletter_v2_headerFor more details and program pricing, please contact:
Shaun Mehr, Media Advisor | (949) 923-1660 | Click here to email your request for more Information

Last Editorial Review: August 29, 2017

Copyright © 2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Manuscript Guidelines & Tips

Skip to toolbar